Skip to main content
Quantum Genomics logo

Quantum Genomics — Investor Relations & Filings

Ticker · ALQGC ISIN · FR0011648971 LEI · 969500TFCD8K9RPM9K97 PA Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2016-05-31 Regulatory Filings
Country FR France
Listing PA ALQGC

About Quantum Genomics

https://quantum-genomics.com/

Quantum Genomics is a biopharmaceutical company focused on developing a new class of medications for cardiovascular diseases with high unmet medical needs, such as difficult-to-treat or resistant hypertension and heart failure. The company's core research is based on a breakthrough therapeutic approach involving the inhibition of Brain Aminopeptidase A (BAPA). Its lead drug candidate, firibastat, is a first-in-class BAPA inhibitor designed to offer a novel treatment mechanism for managing these conditions.

Recent filings

Filing Released Lang Actions
Quantum Genomics symposium at the European Meeting on Hypertension and Cardiovascular Protection
Regulatory Filings Classification · 95% confidence The document is a press release announcing the company's participation and symposium presentation at the European Meeting on Hypertension and Cardiovascular Protection. It details scientific presentations related to their drug candidate QGC001. It also includes a 'Next meetings' schedule, which lists future events, including a 'General Shareholders' Meeting' and 'First half 2016 financial results'. Since the primary content is an announcement about participation in a scientific/industry event and future corporate events, it does not fit the strict definitions of 10-K, ER, IR, or AR. It is not a formal regulatory filing like a DVA or DIRS. It is an announcement about company activities and upcoming events, which is often categorized under general regulatory announcements or investor relations updates. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for corporate news releases that don't fit a more specific financial or governance code, although 'Investor Presentation' (IP) might seem close, this is an announcement *about* a symposium, not the presentation itself. However, since it details upcoming investor-facing events and scientific updates, it functions as general corporate communication. RNS is the most appropriate fallback for non-standard, non-financial-result press releases.
2016-05-31 English
Quantum Genomics granted two new U.S. patents covering lead product QGC001
Regulatory Filings Classification · 93% confidence The document is a press release announcing that Quantum Genomics has been granted two new U.S. patents covering its lead product QGC001. This announcement pertains to intellectual property protection and asset development, which falls under the scope of general corporate news or investor relations updates. Since there is no specific category for 'Patent Grant Announcement,' I must evaluate the provided options. It is not a financial report (10-K, IR, ER), a management change (MANG), a dividend notice (DIV), or a transaction (POS, TAR). The content is highly specific to intellectual property (patents) and R&D assets. While it is a form of corporate disclosure, it doesn't fit the definitions for AGM-R, AR, CT, CAP, DVA, DLST, DIRS, SR, XLSX, FS, CGR, IRAT, IP, LTR, MRQ, MDA, NAV, PSI, DEF 14A, SHA. The most appropriate general category for a specific, non-financial regulatory/corporate update that doesn't fit elsewhere is 'Regulatory Filings' (RNS), as patent grants are official regulatory actions, or potentially 'LTR' if viewed as a legal/IP matter, but RNS is the broader fallback for non-standard announcements. Given the nature of the announcement (patent grant), RNS is the best fit as a general regulatory/corporate update.
2016-05-17 English
Quantum Genomics reçoit deux nouveaux brevets aux États-Unis couvrant son produit phare QGC001
Investor Presentation Classification · 98% confidence The document is a press release ("Communiqué de presse") announcing that Quantum Genomics has received two new patents (US Patent Nos. 9340497 and 9278921) in the United States covering its drug candidate QGC001. The content focuses entirely on intellectual property protection, patent numbers, expiration dates, and the strategic importance of these patents for the company's core product. This type of announcement, dealing specifically with the granting of patents and intellectual property rights, aligns best with the 'Intellectual Property' category, which corresponds to the 'IP' filing code.
2016-05-17 French
Autorisations réglementaires reçues en France pour débuter l'étude européenne multicentrique de phase IIa dans l'insuffisance cardiaque
Legal Proceedings Report Classification · 99% confidence The document is a press release ("Communiqué de presse") dated April 26, 2016, announcing regulatory authorizations received in France (ANSM and CPP) to start a Phase IIa clinical study for heart failure (QGC101 program). It also mentions the completion of another Phase IIa study (QGC001) and confirms that results will be communicated in Q3 2016. This type of announcement, detailing clinical trial progress, regulatory milestones, and upcoming result disclosures, is characteristic of corporate communications in the pharmaceutical/biotech sector. It is not a full financial report (10-K, IR), an earnings release (ER), or a formal shareholder vote result (DVA). Since it is a specific announcement about clinical trial progress and regulatory milestones, it fits best under the general category of Regulatory Filings (RNS) as a miscellaneous, non-financial, non-governance specific announcement, or potentially a Legal Proceedings Report (LTR) if the focus was on litigation, but here it is about trial initiation. Given the options, RNS serves as the best general regulatory/corporate update category for clinical trial progress announcements that aren't explicitly covered elsewhere. The document length (4233 chars) is moderate, but the content is purely informational/update-based, not a full report.
2016-04-26 French
Regulatory authorisations received in France to begin Phase IIa multicentric European trial for heart failure
Regulatory Filings Classification · 90% confidence The document is titled "Press release" and announces that regulatory authorisations have been received to begin a Phase IIa clinical trial for heart failure. It also mentions that results for another trial will be released in Q3 2016. This type of announcement, which communicates key operational and clinical updates, often including timelines for future results, fits best under the general category of an Earnings Release (ER) if it were quarterly results, or more broadly, a Regulatory Filing (RNS) if it doesn't fit a specific operational category. However, since it is a press release detailing significant operational milestones (regulatory approval for a trial) and providing forward-looking information about results release dates, it is a general corporate announcement. Given the options, and that it is not a full financial report (10-K, IR), a specific management discussion (MDA), or a formal dividend/share action, the most appropriate general category for a significant, non-financial-specific operational update disseminated via press release is Regulatory Filings (RNS), as it serves as a broad regulatory/corporate disclosure mechanism. It is not an ER because it is not focused on financial performance highlights, but rather clinical trial progress. It is not an LTR as it is positive news (approval), not a report on legal proceedings. Therefore, RNS is the best fit as a general regulatory disclosure.
2016-04-26 English
Rapport annuel 2015 : accélération des études cliniques, financement sécurisé et internationalisation en cours
Report Publication Announcement Classification · 95% confidence The document is a press release from Quantum Genomics announcing the availability of its 2015 Annual Report on its website. While it contains some financial highlights (revenue, cash flow, net results), it is primarily an announcement of the report's publication rather than the full annual report itself. According to the 'Menu vs Meal' rule, documents that announce the availability of a report are classified as Report Publication Announcements (RPA). FY 2015
2016-04-14 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.